Ranitidine and the FDA Recall

| May 1, 2020 | Uncategorized |

In April 2020, the FDA announced that Zantac, or Ranitidine, will be recalled because of a probable carcinogen in the drug. There are many sources of the carcinogen, NDMA. The Ranitidine molecule itself can create it, but the risk is particularly high because this isn’t the only means of NDMA’s creation.The risk increases with hot temperatures, and length of time since manufacturing. Zantac was once unanimously thought of as a safe drug, and at times, the most popular drug in the world. Now, patients will need to find an alternative.

References:

Zantac Cancer FDA Recall